Public evidence supports a large national medicine market, but this research did not identify a defensible market-size series specifically for providers with 10–100 prescribers. The national benchmarks below should frame a procurement strategy, not substitute for a bottom-up provider census.
Which spending figures are usable?
| Measure | Figure and observation period | Basis and limitation | Source and publication date |
|---|---|---|---|
| US GLP-1 spending across the broader category | Approximately $128 billion in 2025 — analyst calculation | ASHP reported approximately 14% of $915 billion in total prescription spending. Multiplication gives $128.1 billion; rounded because the underlying share is approximate. ASHP says direct-to-consumer sales are excluded. Includes more than obesity treatment. | ASHP, April 30, 2026 |
| US GLP-1 antiobesity medicine spending | $41.6 billion, 2025 | Reported pharmaceutical purchase expenditure; not clinic revenue or manufacturer net revenue. | AJHP, April 30, 2026 |
| Increase in US net spending attributable to GIP/GLP-1 agonists | $14 billion, 2025 versus 2024 | Growth contribution across diabetes and obesity—not total category spending. | IQVIA, April 28, 2026 |
| Obesity-related component of that net-spending increase | $9.6 billion, 2025 versus 2024 | Included within the $14 billion above; do not add the two figures. | IQVIA, April 28, 2026 |
| Procurement controlled by the target provider cohort | Not established | Requires provider counts, active patients, access-route mix and evidence of who controls expenditure. | Research gap as of November 17, 2026 |
The approximately $128 billion calculation and the $41.6 billion obesity figure are overlapping measures, not additive market segments. IQVIA’s net-spending growth also uses a different economic basis from purchase expenditure. Its report explicitly distinguishes list-price and net-price measures. IQVIA methodology and findings
What do the latest manufacturer results show?
| US commercial indicator | Q3 2026 observation | Comparison | Source |
|---|---|---|---|
| Mounjaro revenue | Approximately $5.0 billion | 41% growth versus Q3 2025 | Lilly, October 29, 2026 |
| Zepbound revenue | Approximately $5.3 billion | 48% growth versus Q3 2025 | Lilly, October 29, 2026 |
| Novo Nordisk obesity sales | 20% growth at constant exchange rates | Q3 2026 versus Q3 2025 | Novo Nordisk, November 4, 2026 |
| Novo Nordisk injectable Wegovy sales | 13% decline at constant exchange rates | Q3 2026 versus Q3 2025 | Novo Nordisk, November 4, 2026 |
Buyer interpretation: product and channel mix matter more than a single market-growth headline. Novo’s obesity franchise growth alongside declining injectable Wegovy sales illustrates why a clinic should forecast oral, injectable, insured and self-pay activity separately. This is an inference from the reported results, not a forecast of any provider’s growth. Novo Nordisk results
Do not divide these revenues by prescription counts from another source to manufacture a “net price per patient.” The numerator and denominator may cover different channels, recognition periods and patient populations.
Explore the table row by row
A working view of the research
US GLP-1 spending across the broader category
- Figure and observation period
- Approximately $128 billion in 2025 — analyst calculation
- Basis and limitation
- ASHP reported approximately 14% of $915 billion in total prescription spending. Multiplication gives $128.1 billion; rounded because the underlying share is approximate. ASHP says direct-to-consumer sales are excluded. Includes more than obesity treatment.
- Source and publication date
- ASHP, April 30, 2026
Sources cited on this page
- news.ashp.org · Source 1 ↗https://news.ashp.org/news/ashp-news/2026/04/30/us-prescription-drug-spending-poised-to-cross-1-trillion-with-weight-loss-drugs
- academic.oup.com · Source 2 ↗https://academic.oup.com/ajhp/article/83/14/728/8662887
- iqvia.com · Source 3 ↗https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026
- lilly.gcs-web.com · Source 4 ↗https://lilly.gcs-web.com/node/55191/pdf
- sec.gov · Source 5 ↗https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm